Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.3 pts less than Nifty Microcap 250 and 4.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals reported Q2 FY26 revenue from operations of ₹744.65 million, nearly flat versus ₹746.92 million in Q2 FY25. For H1 FY26, revenue from operations grew about 10% year-on-year to ₹1,500.77 million (vs ₹1,361.31 million). Net profit for the quarter stood at ₹107.95 million (vs ₹114.59 million), while H1 FY26 net profit jumped around 39% to ₹233.69 million (vs ₹167.88 million), helped by a low base last year which had an exceptional item charge of about ₹32.85 million. EPS for the half year was ₹3.48 versus ₹2.52. The statutory auditor Walker Chandiok & Co LLP issued an unmodified limited review report.
Sharp H1 profit growth and stable margins signal healthy operating performance, though the headline quarter was soft with revenue and profit slightly lower year-on-year. The clean auditor report and dividend payout of ₹2.5/share (₹166.58 million) are positive signals for shareholders.